All In Biotech

Drug Trial Radar · NCT05212896

An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors

An Exploratory Clinical Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BC006 Monoclonal Antibody Injection in Patients With Advanced Solid Tumors Including Giant Cell Tumor of Tendon Sheath

Last checked: Nov 19, 2026Latest source record: Jan 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 26, 2021

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Sponsor type
Industry
Collaborators
West China Hospital
First posted
Jan 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.

Conditions

  • Advanced Solid Tumors (Including GCTTS)

Interventions

  • BC006Drug

    BC006 monoclonal antibody injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Maximum Tolerated Dose (MTD) of BC006Time frame: Up to 28 days
  3. Recommended Dose for Expansion (RDE) of BC006Time frame: Through study completion, an average of 1 year
  4. Number of Participants with TEAEsTime frame: Through study completion, an average of 1 year
  5. Number of Participants with SAEsTime frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dragonboat Biopharmaceutical,Co.,Ltd

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.